🤯 Early Bird Alert Inside, Revealed Today!

This company has been profiled by us before and went up 56% in just 2 day's, Now this is an early bird alert for TUESDAY 1/31 to finish January! [View online]( [UNSUBSCRIBE]( -*ADVERTORIAL*- There’s a good reason why Insiders are loading up on this $1.36 healthcare company. Greetings All, Everybody needs healthcare -- or will, at some point. And, when there’s something everyone needs, there’s a huge opportunity. The pandemic was undoubtedly a very stressful time for many people including healthcare workers. The high-stress environment caused a significant impact on frontline workers like nurses who often worked extra hours and were responsible for ensuring a sufficient medication supply was available. They also had to avoid disruptions while caring for patients. The potential for errors can increase in these types of high-stress situations but one way to reduce the risk of errors is to use manufacturer-prepared, ready-to-administer (RTA) prefilled syringes, when appropriate. NEW ALERT: NASDAQ: STSS Through its recent product launch announcement, emerging NASDAQ company Sharps Technology, Inc. (NASDAQ: STSS) is addressing multiple problems in the syringe system market by modernizing the prefillable space with its polymer-based product line. Over the last 20 years, the pharmaceutical syringe operational model has shifted from the use of glass vials and bulk disposable syringes to next-generation prefillable syringes, increasing prefillables from 15% to 85% share. This has contributed to market expectations of $15.7 Billion in revenue for 2030 from [$5.6 Billion reported in 2020]( for prefillables. Major companies in the space include syringe system manufacturers such as Becton Dickson and Co. (NYSE: BDX) and Cardinal Health (NYSE: CAH). BDX is over $200 a share while CAH is over $70 a share. STSS is only trading at around $1.36 and is carving a unique position for itself in a highly addressable market with its specialty polymer-based syringe systems that are in significant demand! The stock boasts a STAY LONG rating at AmericanBulls.com and also has a relatively tiny trading float at just [5.6M shares]( making for a limited amount of shares available… Now may be the best time to have STSS high on your radar! Sharps Technology, Inc. (NASDAQ: STSS) is an innovative medical device and drug delivery company offering patented, best-in-class syringe products. The company aims to serve healthcare and pharmaceutical customers that recognize the advantages of non-glass products. BULLISH RATING Currently STSS has a STAY LONG rating at [AmericanBulls.com.]( The Problem The use of standard syringes that are not designated as low waste or ultra-low waste products typically creates a dead space area within the syringe where excess medication is trapped and cannot be used. This dead space then causes the healthcare provider to throw away the unused medication. The trapped medication in the dead space of a standard syringe can waste as much as 100 microliters (uL) of medication or more! The Pharmaceutical companies that fill their medication into vials understand this and must then overfill the vial with drug therapy to compensate for the problem. As the costs for medication and medical treatments rise, the discarded medication can cost the industry millions of dollars, or more, globally. The Solution STSS has developed a high-quality alternative solution to glass syringes through the use of inert polymers such as Cyclic Olefin Polymer (COP) and Cyclic Olefin Copolymer (COC), which offers a high-quality solution as compared to traditional glass syringe systems. These polymer syringes have many of the same characteristics as current pharmaceutical glass designs to support long-term drug stability and increase shelf life for customers in the pharmaceutical segment. Polymer syringes can also be made into custom configurations, which function to eliminate breakage, minimize dead space, reduce contamination, and support the development of custom devices including autoinjectors. STSS is also making a silicone-free prefillable product that addresses silicone interaction issues for the broader healthcare market. Currently, syringes are commonly made with medical-grade silicone, but utilizing siliconeand can result in drug contamination, adding a need for costly inspections every time syringes are filled. The company’s silicone-free solution removes the risk of interaction with biologics and eliminates the need for product inspections and potential product waste issues. ENTERING REVENUE PHASE STSS is a remarkable company to have on your radar right now especially because they are headed towards the revenue phase now! The company is transitioning from a research and development company into commercial operations through a [major partnership signed with Nephron Pharmaceuticals in November 2022](. This collaboration will boost STSS’s ability to reach out to the prefillable syringe market. With manufacturing, sales and marketing solidified, the company is confident in its ability to execute on multiple revenue opportunities in the growing prefillable market. Initial demand will be supported by manufacturing capacity of 20+ million units, with additional capacities that can be scaled by 2025 with an additional 100 million units annually. Products will be manufactured utilizing state-of-the-art injection molding technologies with highly automated assembly lines. STSS believes this increased production capacity and distribution will allow it to [fill a growing market]( that is looking for innovative prefillable solutions. Nephron’s InjectEZ program will increase manufacturing out of its South Carolina operations and the use of their manufacturing facility will advance STSS’s development strategy by two years! STSS will also get full access to Nephron’s lab capabilities, providing the company with the opportunity to continue to innovate for ongoing product development. “Following years of research and development, Sharps is now in a position to commercialize and support the future of specialty syringe drug filling technology. The opportunity to advance our product and manufacturing strategy to include high-value prefillable syringe products will significantly accelerate our revenue growth for 2023 and beyond.” - Robert Hayes, Sharps Chief Executive Officer. Each year almost [ 20 billion injections]( are administered, globally. WHO are advocating for the use of low waste space syringes, passive safety devices which engage automatically and auto-disable features. STSS’s commercialization and growth strategies also include joint presentations with their pharmaceutical partner, to service the pharmaceutical industry with specialty drug delivery products produced in the US. European Facility STSS’s purchase of the European facility in Hungary was finalized in the summer of 2022 and the company has invested in infrastructure and equipment upgrades to prepare the plant for a full manufacturing schedule. Syringe products produced by Sharps comply with all applicable FDA and ISO requirements and have been awarded the European Union’s CE Mark. The Sharps Hungary team, led by General Manager Filippo Filippi, brings together a dedicated and knowledgeable manufacturing force, with more than 20 years of experience in supplying the world with high quality, innovative syringe products. Prior to the GM position, Filippi’s career spanned years of building, managing, and supporting multiple manufacturing sites across Europe, Asia, and Africa. The Hungary plant is vertically integrated in that it has the capability to manufacture the syringe components by injection molding, assemble the devices on automated lines or by manual assembly if required, and to sterilize the products on-site through the Ethylene Oxide (EtO) sterilization process. This last stage of the syringe manufacturing process is unique in the industry and gives Sharps an advantage in supporting shortened lead times as compared to the common need to utilize a third-party for sterilization. The plant has manufacturing capacity to supply more than 50 million units today and the facility could be expanded to produce 250 million units or more over the next couple of years. Pre-filled Syringes Market Pre-filled syringes have emerged as one of the fastest-growing choices for unit-dose medication as the pharmaceutical industry seeks new and more convenient drug delivery methods. With PFS/RTF syringes, pharmaceutical companies are able to minimize drug waste and increase product life span, while patients are able to self-administer injectable drugs at their home instead of the hospital. Ready-To-Use - Pre-Filled Syringes: - Types: Plastic and Type I B/S Glass - Applications: Vaccines, Diabetes, Complex High Value Therapies (Gene-Therapy) - End Users: Branded Pharma, CMOs and Biologics - Target Markets: North America Growing demand for efficient and easy-to-use drug delivery devices and increasing efforts of healthcare professionals to reduce hospital errors are the principal factors driving the market growth. The Vaccines Market The [global vaccines market]( is projected to grow from $61.04 billion in 2021 to $125.49 billion in 2028 at a CAGR of 10.8% in the forecast period, 2021-2028. Vaccines are the most powerful and cost-effective way to protect billions of people in the world. According to the [WHO]( immunization awareness and government initiatives have helped prevent 2-3 million deaths a year. Great investments along with merging and partnerships of companies are boosting the production and sales of products globally. The rise in the need for vaccinations and immunizations, plus a surge in the geriatric population, an increase in the number of surgical procedures, as well as a rise in chronic diseases have contributed to a demand for syringes. Specialty Syringes - Vial Application - Global Smart Syringe Market @ $14 billion USD by 2026 w10.0%+ CAGR - Types: Auto-Disable Syringes and Safety Syringes - Applications: Vaccination and Drug Delivery - End Users: Hospitals, HMOs and Clinics - Target Markets: North America, Europe and ROW - Sharps Technology listed as a supplier Source: © Infinium Global Research The PFS/RTF syringe product segment especially will be a priority for the company created through its collaboration with Nephron. This product segment is expected to be significant in revenue and profitability goals! In Summary…. STSS is the newest player in the drug delivery device market to go public (last year!) and could see tremendous blue-sky growth in its future as it continues to ramp up its commercialization efforts. The modern world received a major wake-up call because of the pandemic. The essence of progress in healthcare has become one of the biggest bright sides these last few years. The pandemic has had a substantial impact on immunization and vaccination activities. Many people have no idea that most syringes waste significant amounts of injectable medicine which are thrown away with the used needle/syringe. This adds to cost and reduces the amount of life-saving injectable drugs which are available to us all. Whether a pandemic, hard-to-manufacture drugs, or long-term chronic illness, we can't afford to waste this precious supply. This will further bring attention to the relatively unknown Sharps Technology Inc. (NASDAQ: STSS) which is offering the world better drug delivery technology. The fact that multiple insiders have loaded up ([39.41% insider ownership]( sends a positive message that they believe in the company’s value. 2023 could be a monumental year for the company and shareholder growth! Start your research now!     Copyright 2023 © TopStockTips.com is owned and operated by the owner of CareBear Marketing Group LLC and IR Agency LLC (www.IR.Agency). Disclaimer and Privacy For more Information please contact Support@TopStockTips.com CareBear Marketing LLC and IR Agency LLC and their affiliates and control persons (the “Publisher”) are in the business of publishing favorable information and/or advertisements (the “Information”) about the securities of publicly traded companies (each an “Issuer” or collectively the “Issuers”) in exchange for compensation (the “Campaigns”). Persons receiving the Information are referred to as the “Recipients.” The person or entity paying the Publisher for the Campaign is referred to herein as the “Paying Party”. The Paying Party may be an Issuer, an affiliated or non-affiliate shareholder of an Issuer or another person hired by the Issuer or an affiliate or non-affiliate shareholder of the Issuer. The nature and amount of compensation paid to the Publisher for the Campaign and creating and/or publishing the Information about each Issuer is set forth below under the heading captioned, “Compensation”. This website provides information about the stock market and other investments. This website does not provide investment advice and should not be used as a replacement for investment advice from a qualified professional. This website is for informational purposes only. The Author of this website is not a registered investment advisor and does not offer investment advice. You, the reader, bear responsibility for your own investment decisions and should seek the advice of a qualified securities professional before making any investment. Nothing on this website should be considered personalized financial advice. Any investments recommended here in should be made only after consulting with your personal investment advisor and only after performing your own research and due diligence, including reviewing the prospectus or financial statements of the issuer of any security. CareBear Marketing Group and/or IR Agency LLC, its managers, its employees, affiliates, and assigns (collectively the "Publisher") do not make any guarantee or warranty about the advice provided on this website or what is otherwise advertised above. To the maximum extent permitted by law, the Company disclaims all liability in the event any information, commentary, analysis, opinions, advice and/or recommendations provided herein prove to be inaccurate, incomplete, or unreliable, or result in any investment or other losses. You received this message as part of your subscription to TST. TST is a free financial news and information website. We do not directly sell any products or offer any personal financial advice, nor do we advocate the purchase or sale of any security or investment for any specific individual. We also do not make any guarantee or warranty about what is advertised above. If you have questions or concerns about a product you’ve seen in one of our emails, we encourage you to reach out to that company directly. Disclaimer – Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated, and edited by the owner of CareBear Marketing Group and IR Agency LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” or “TST” refers to CareBear Marketing Group and/or IR Agency LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore unqualified to give investment recommendations. Companies with low prices per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service, you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and its owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares, we will list the information relevant to the stock and the number of shares here. We do not own any shares in STSS, because we do have a relationship with a company (Tradigital Marketing Group) that does own shares please see their disclaimer here: . We have been compensated up to Four-Hundred Thousand Dollars Cash ($400,000) via credit card processing for lead generation, content distribution and other digital marketing efforts from a third-party Open Market Media Inc for a 2 Month Marketing Program regarding STSS with a start date of 11/28/2022 to 01/31/2023.TST’s business model is to receive financial compensation to promote public companies. This compensation is a major conflict of interest in our ability to be unbiased regarding our alerts. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, TST often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice. If you clicked on a link to this page, then this Disclaimer is applicable to the Information you received or will receive about the Issuers mentioned under the heading “COMPENSATION” at the bottom of this Disclaimer. METHODS OF DISSEMINATION The Publisher may use various types of media (the “Media”) to disseminate the Information, at its discretion without notice to Recipients. The Information may be published on and/or through any or all the non-exclusive methods below: Ticker Tags (as defined under heading “DISCLAIMERS AND RISKS” websites owned, controlled and/or operated by the Publisher including but not limited to; TopStockTips.com, PTE.la, MomentumStocks.io, BullishCharts.com; websites owned and/or operated by the Publisher’s affiliates and non-affiliates, online communities, financial forums, trader and investor chat rooms, social media platforms and/or newsletters using online identities some or all of which may or may not be anonymous, text message alerts, audio services, online live interviews, news outlets located, coordinated or paid by the Publisher, email communications, and other communications sent to the Recipients from time to time. push notifications influencers podcasts online interviews audio ads banner ads native ads responsive ads DISCLAIMERS AND RISKS An investment in the Issuers is subject to numerous risks including but not limited to those set forth in this Disclaimer. Some but not all of these risks include: Ticker Tagging attaches an Issuer’s name and symbol to that of a larger more successful company to create interest. Ticker Tags are click bait to get a reader’s attention so that they click on a link. Information contained in Ticker Tags is not true or complete and its sole purpose is to cause a Recipient to click a link to a webpage so that the Recipient is provided with the Information. The Campaigns vary between Issuers. Campaigns may consist of dissemination though one or more types of Media while other Campaigns may use one or more different types of Media. Different types of Media may be disseminated at different times to different Recipients. Some types of the Media may be disseminated for longer periods of time than other types of Media. The Media may be coordinated in a manner designed to create an increase in the volume and trading price of an Issuer’s securities for a temporary period of time. You should not consider increases in volume and price of an Issuer’s securities during a Campaign as an indication or measure of value or price. The Publisher may disseminate the Information multiple times and at different times that are minutes, hours, days, weeks or even months apart. As such, the Information may be viewed by Recipients at different times that are minutes, hours, days or even weeks apart. Typically, the earlier the Recipient receives the Information, the lower the price at which he or she can purchase an Issuer’s securities. As a result, the later a Recipient receives the Information, the more likely it is that the Recipient will suffer increased trading losses if he purchases the securities of an Issuer. Recipients who receive the Information at later times will likely pay prices which are higher than the prices paid by Recipients who receive the information earlier in the Campaign. Temporary volume and price increases will likely result from Recipients buying an Issuer’s securities during the Campaign. If you invest in an Issuer’s securities based upon these temporary volume and price increases, you will likely lose your investment. The Publisher does not publish negative information because it is compensated to publish only favorable information. The Information is a one-sided incomplete favorable snapshot and as such, the Information is not balanced, complete, accurate, truthful or reliable. If you rely on the Information in making an investment decision, you will likely lose your investment. The Information does not include the information necessary to make an informed investment decision. If you rely on the Information in making an investment decision, you will likely lose your investment. If you invest in the Issuers, you should be prepared to lose your entire investment without a change to your standard of living. The Publisher receives the Information from the Issuer, Paying Party or other sources such as press releases, stock message boards or websites, the OTC Markets, Google, NASDAQ, NYSE, Yahoo, Bing, the Securities and Exchange Commission’s (“SEC”) Edgar database or other available sources. Information derived from these sources should not be deemed to be reliable, true or complete. The Publisher does not verify or assert the truthfulness, completeness, accuracy or reliability of the Information. The Publisher conducts no due diligence or investigation of the Issuers or their securities and it does not receive any verification from the Issuers concerning the truthfulness or completeness of the Information. The Publisher does not review, nor does it have the sophistication or resources necessary to analyze the financial condition, operations, business, management, risks or prospects involved in an investment in the securities of any of the Issuers. If you rely on the Information in making an investment decision, you will likely lose your investment. Past results of an Issuer do not guarantee future performance. The Information should not be interpreted in any way, shape, form or manner whatsoever as an indication of an Issuer’s future stock price or future financial performance. If you rely on the Information in making an investment decision, you will likely lose your investment. If the Information states that an Issuer’s securities are consistent with a future economic trend, then it should not be relied upon and should be considered as satire or an error. Even if a Recipient’s own independent research indicates that an Issuer’s securities are consistent with future economic trends, each Recipient should be aware that economic trends have their own limitations, including: (a) that economic trends or predictions may be speculative; (b) consumers, producers, investors, borrowers, lenders and government may react in unforeseen ways and be affected by behavioral biases that The Publisher is unable to predict; (c) human and social factors may outweigh future economic trends that the Publisher state may or will occur; (d) clear cut economic predictions have their limitations in that they do not account for the fundamental uncertainty in economic life, as well as ordinary life; (e) economic trends may be disrupted by sudden jumps, disruptions or other factors that are not accounted for in economic trends analysis; in other words, past or present data predicting future economic trends may become irrelevant in light of new circumstances and situations in which uncertainty becomes reality rather than predicted economic outcome; or (f) if the trend predicted involves a single result, it ignores other scenarios that may be crucial to make a decision in the event of unknown contingencies. If you rely on the Information in making an investment decision, you will likely lose your investment. The Publisher is not nor is it qualified to act as: (i) an investment adviser or an entity engaging in activities that would be deemed to be providing investment advice that requires registration either at the federal or state level, (ii) a broker-dealer or an individual acting in the capacity of a registered representative or broker-dealer, (iii) a stock picker, (iv) a securities trading or investment expert, (v) a securities researcher or analyst, (vi) a financial planner or one who engages in financial planning, (vii) a party who provides advice about buy, sell or hold recommendations as to specific securities; (viii) a clairvoyant, physic or fortune teller, or (ix) a party or an agent offering securities for sale or soliciting their purchase. References in the Information that refer to a security as a “stock pick” means it is a stock advertised by the Publisher and is not an indication the Issuer or its securities have been picked, chosen, selected, researched or recommended by the Publisher or that the Publisher is qualified to pick, chose, select, research or recommend investments or securities. If you rely on the Information in making an investment decision, you will likely lose your investment. The Information should only be used, at most, and if at all, as a starting point for a Recipient to conduct a thorough investigation of the Issuer and its securities. If a Recipient relies on the Information in making an investment decision, the Recipient will likely lose most, if not all, of his or her investment. Under no circumstances should Recipients rely on the Information to make an investment decision or for any other purpose. If you rely on the Information in making an investment decision, you will likely lose your investment. There is a high degree of risk in an investment in the securities of the Issuers. Recipients may encounter difficulties determining what, if any, portions of the Information are material or non-material, making it all the more imperative that each Recipient conducts its own independent investigation of the Issuer and its securities with the assistance of its legal, tax and financial advisors. Each Recipient is expressly advised to consult with its own financial, legal or other advisers prior to an investment in the securities of an Issuer. Recipients should review with these advisers, the filings and information that may be accessed at sec.gov or www.otcmarkets.com including: (i) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D), and (ii) reviewing Information and Disclosure Statements and financial reports filed with the OTCMarkets.com. Issuers may not be current in their reporting obligations with the SEC and the OTC Markets and/or their securities could have negative legends and designations at otcmarkets.com. Additionally, Recipients and their advisors should obtain and review: (i) publicly available information contained in commonly known search engines such as google, and (ii) investment guides at www.sec.gov and www.finra.org. If an Issuer is an SEC reporting company, it could be delinquent (not current) in its periodic reporting obligations (i.e., in its quarterly and annual reports) with the SEC, or if it is an OTC Markets Pink Sheet quoted company, it may be delinquent in its Pink Sheet reporting obligations, which may result in OTC Markets posting a negative legend pertaining to the Issuer at www.otcmarkets.com, as follows: (i) “Limited Information” for companies with financial reporting problems, economic distress, or that are unwilling to file required reports with the Pink Sheets; (ii) “No Information,” which characterizes companies that are unable or unwilling to provide any disclosure to the public markets, to the SEC or the Pink Sheets; and (iii) “Caveat Emptor,” signifying buyers should be aware that there is a public interest concern associated with a company’s illegal spam campaign, questionable stock promotion, known investigation of a company’s fraudulent activity or its insiders, regulatory suspensions or disruptive corporate actions. Recipient’s use of the Information is at its own risk. The Information is provided “as is” with no warranties of any type, without limitation. The Publisher is not responsible or liable for any person’s use of the Information or any success or failure that is directly or indirectly related to such person’s use of the Information because the Publisher has specifically stated that the information is not reliable and should not be relied upon for any purpose including an investment. The Publisher is not responsible for omissions or errors in the Information and the Publisher is not responsible for actions taken by any person who relies upon the Information. The Publisher makes no warranty or representation about the Information, including its completeness, accuracy, truthfulness or reliability. The Publisher disclaims, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. The Publisher, the Paying Party or other service providers including stock promoters and advertisers (“Selling Parties”) could receive free-trading securities of an Issuer: (i) as compensation, (ii) in private or open market transactions at prices lower than the market price or price paid by Recipients, and/or (iii) in open market transactions before, during and after the Campaigns. Selling Parties may sell their securities of an Issuer at any time during the Campaigns, even while the Publisher publishes the Information instructing or encouraging Recipients to purchase securities of the Issuer. When Selling Parties sell their securities, the volume and trading price of the Issuer’s securities will likely decline. This will reduce the price at which Recipients can sell their securities and likely cause Recipients to suffer trading losses. Selling Parties may sell securities of the Issuers for less than the target prices set forth in the Information and Selling Parties may profit by selling its securities during the Campaigns while Recipients have a loss. When Selling Parties acquire, purchase or sell the securities of an Issuer, it could (i) cause significant volatility in the Issuer’s securities; (ii) if purchasing, cause temporary but unrealistic increases in volume and price of the Issuer’s securities; and (iii) if selling, cause the Issuer’s stock price and trading volume to decline dramatically resulting in Selling Parties making substantial profits while Recipients who purchase during the Campaign experience significant losses. The Campaigns are designed to increase the trading price of the Issuers’ securities by encouraging the Recipients of the Information to purchase an Issuer’s securities despite that the securities may not be a good investment, and the trading price of the Issuer’s securities will dramatically decline when the Campaign ends. If you rely on the Information in the Campaigns when making an investment decision, you will likely lose your investment. If the Issuer’s trading price increases during the Campaign, it is likely the result of buying activity caused by the Campaign and such increase does not reflect the Issuer’s prospects, financial condition or an increase in the value of the Issuer’s securities. If you rely on this buying activity when making an investment decision, you will likely lose your investment. If Selling Parties hold or are compensated in improperly free-trading securities of the Issuers, either directly or indirectly, the Selling Parties and the Issuer could be the subject to an SEC Enforcement action, including allegations of an illegal distribution in violation of Section 5(a) and 5(c) of the Securities Act which could cause you to lose your investment. The Publisher may hire service providers to disseminate the Information about the Issuers and the Publisher may not have control over such parties. The Publisher does do not verify the Information it receives from any party or information disseminated by other service providers. As such, you should not rely on the Information when making an investment decision. The Information may contain statements asserting that an Issuer’s stock price has increased over a certain period of time which may reflect an arbitrary period of time, and such statements are not predictive or of any analytical quality. As such, Recipients should not rely on the Information as an analysis of the present or future potential of an Issuer or its securities. If you rely on the Information, you will likely lose your investment. If any percentage gain of an Issuer’s securities from the previous day’s close is included in the Information, it is not and should not be construed as an indication that the future stock price or future operational results will reflect gains or otherwise prove to be advantageous to an investment in an Issuer. If you rely on the previous days close as an indication of performance, it could cause you to lose your investment. Past results of an Issuer do not guarantee future performance. The Information should not be interpreted in any way, shape, form or manner whatsoever as an indication of an Issuer’s future stock price or future financial performance. Recipients should consider the securities of the Issuers as high risk, unstable, unpredictable and illiquid which may make it difficult for Recipients to sell any securities of the Issuers that they purchase. During the Campaign the trading volume and price of the securities of each Issuer will likely increase significantly. When the Campaign ends, the volume and price of the Issuer will likely decrease dramatically. As a result, Recipients who purchase during the Campaign or as a result of the Campaign will probably lose most, if not all, of their investment. MM’s publication of the Information involves actual and material conflicts of interest including but not limited to the following: The Publisher receives monetary and/or securities compensation in exchange for disseminating the Information about the Issuers. The Publisher only publishes favorable information about the Issuers and does not publish any negative information about the Issuers. The Paying Parties likely hold securities of an Issuer which they acquired from the Issuer, affiliate or non-affiliate shareholders or from its own open market purchases before, during or after the Campaign. The Paying Parties may have acquired these securities for services or at prices lower than that paid by Recipients. The Paying Parties may sell these securities during the Campaign while the Publisher publishes the Information recommending that Recipients purchase. Selling by a Paying Party will likely cause Recipients who purchase securities of any of the Issuers to suffer losses. DISCLAIMER COMPENSATION We do not own any shares in STSS, because we do have a relationship with a company (Tradigital Marketing Group) that does own shares please see their disclaimer here: . We have been compensated up to Four-Hundred Thousand Dollars Cash ($400,000) via credit card processing for lead generation, content distribution and other digital marketing efforts from a third-party Open Market Media Inc for a 2 Month Marketing Program regarding STSS with a start date of 11/28/2022 to 01/31/2023. , Rua Frei Tome de Jesus N18 1Dto, 1700-215, Lisboa, Portugal You may [unsubscribe]( or [change your contact details]( at any time. Powered by:[GetResponse](